In August 2020, the Company adopted the 2020 Stock Plan, or the 2020 Plan, which provides for the granting of stock options to employees, directors and consultants of the Company. Stock options granted under the 2020 Plan may be either incentive stock options, or ISOs, nonqualified stock options, or NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards or other stock awards. ISOs may only be granted to Company employees (including officers and directors who are also employees). Stock awards other than ISOs may be granted to company employees, directors and consultants.

The maximum term of each stock option grant is ten years. The exercise price of ISOs and NSOs granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant as determined by the Company’s board of directors.

In April 2021, prior to the IPO closing, the Company’s board of directors and stockholders approved the 2021 Equity Incentive Plan, or the 2021 Plan, which became effective upon the IPO closing. The Company initially reserved 2,900,000 shares of common stock for issuance of share-based compensation awards, including ISOs, NSOs, stock appreciation rights, restricted stock units and other stock-based awards. ISOs may be granted only to Company employees (including officers and directors who are also employees). Shares of common stock subject to awards granted under the 2020 Plan that are forfeited or lapse unexercised will be available for issuance under the 2021 Plan. Once the 2021 Plan became effective, no further grants were made under the 2020 Plan.

Options under the 2021 Plan may be granted for periods of up to 10 years at exercise prices no less than the fair market value of the Company’s common stock on the date of grant; provided, however, that the exercise price of an ISO granted to a 10% stockholder may not be less than 110% of the fair market value of the shares on the date of grant and such option may not be exercisable after the expiration of five years from the date of grant. Vesting conditions determined by the plan administrator may apply to stock options and may include continued service, performance and/or other conditions. Generally, options and restricted stock units vest over a four-year period.

Upon the closing of the IPO, 485,581 shares available under the 2020 Plan were canceled. In January 2023, the number of shares of common stock available for issuance under the 2021 Plan was increased by 1,252,287 shares as a result of the automatic increase provision in the 2021 Plan.


			Shares Available for Grant
Shares available for grant as of January 1, 2021			818,889
Authorized			2,900,000
Retired			(485,581)
Granted/Awarded			(1,218,021)
Canceled			117,463
Shares available for grant as of December 31, 2021			2,132,750
Authorized			1,222,649
Granted/Awarded			(2,260,197)
Canceled			340,308
Withheld for taxes			8,436
Shares available for grant as of December 31, 2022			1,443,946


	Options Outstanding
	Number of Shares	Weighted-Average Exercise Price		Weighted Average Remaining Contractual Term (in Years)
Balances as of January 1, 2021	2,835,265	$	0.03	9.57
Granted	588,980	$	13.40
Exercised	(300,768)	$	0.03
Canceled	(84,507)	$	0.48
Balances as of December 31, 2021	3,038,970	$	2.61	8.83
Granted	690,218	$	7.83
Exercised	(157,447)	$	0.03
Canceled	(125,158)	$	6.99
Balances at December 31, 2022	3,446,583	$	3.61	8.06
Vested and exercisable at December 31, 2022	1,682,772	$	2.13	7.76
Vested and expected to vest at December 31, 2022	3,446,583	$	3.61	8.06

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock for stock options that were in-the-money at period end. The total intrinsic value of stock options exercised was $0.9 million and $2.3 million during the years ended December 31, 2022 and December 31, 2021, respectively, determined at the date of each stock option exercise.

The terms of the Company’s 2020 Plan permit the exercise of options granted under the plan prior to vesting, subject to required approvals. Shares of common stock issued from the early exercise of unvested stock options are restricted and continue to vest over the original implied service period. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. Shares purchased by employees and non-employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding until those shares vest. The cash received in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options in accrued liabilities on the accompanying balance sheets and will be transferred into common stock and additional paid-in capital as the shares vest. As of December 31, 2022 and December 31, 2021 there were 78,389 and 174,171 early exercised options subject to repurchase, respectively.

In April 2021, the Company adopted the 2021 Employee Stock Purchase Plan, or ESPP. The Company allows eligible employees to purchase shares of the Company's common stock through payroll deductions at a price equal to 85% of the lesser of the fair market value of the stock as of the first date or the ending date of each offering period, which is typically six months. There were 580,000 shares of common stock initially reserved for issuance under the ESPP. In January 2023, the number of shares of common stock available for issuance under the ESPP was increased by 250,457 shares as a result of the automatic increase provision in the ESPP.

The Company issued 284,758 and 109,831 shares under the ESPP for the years ended December 31, 2022 and December 31, 2021, respectively. As of December 31, 2022, 429,940 shares under the ESPP remain available for purchase. The offering period and purchase period is determined by the board of directors. A new offering period of six months has been authorized beginning December 7, 2022 through June 6, 2023.


	Number of Shares Underlying Outstanding Restricted Stock Units	Weighted Average Grant Date Fair Value
Unvested, January 1, 2021	—	$	—
Granted	629,041	$	22.14
Canceled	(32,956)	$	23.58
Unvested, December 31, 2021	596,085	$	22.06
Granted	1,569,979	$	7.72
Vested	(194,705)	$	22.78
Canceled	(215,150)	$	13.95
Unvested, December 31, 2022	1,756,209	$	10.15

As of December 31, 2022, the total unrecognized stock-based compensation expense related to unvested stock options and restricted stock units was $19.8 million, which will be amortized on a straight-line basis over a weighted average remaining period of 2.8 years.

The total fair value of options that vested during the years ended December 31, 2022 and December 31, 2021 was $1.8 million and $0.4 million, respectively. The options granted during the years ended December 31, 2022 and December 31, 2021 had a weighted average grant date fair value of $7.83 per share and $7.78 per share, respectively.


	Year Ended December 31,
	2022	2021
Expected term (in years)	5.27 - 6.25	6.00 - 6.25
Expected volatility	50% - 52%	50% - 53%
Weighted average risk-free interest rate	1.79% - 3.56%	0.59% - 1.33%
Fair value of common stock	$6.30 - $8.15	$0.40 - $21.67
Dividend yield	—%	—%

The expected term of stock options represents the weighted-average period the stock options are expected to remain outstanding. The Company does not have sufficient historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term of options and has opted to use the “simplified method,” whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. The expected stock price volatility assumption was determined by a combination of the Company’s historical stock trading volatility and the historical volatilities of industry peers, as the Company does not have sufficient trading history to solely rely on the volatility of its common stock. The Company will continue to analyze the historical stock price volatility and expected term assumptions as more historical data for the Company’s common stock becomes available. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company’s stock options. The expected dividend assumption is based on the Company’s history and expectation of not to declare and pay dividends.

Prior to the IPO the fair value of the Company’s common stock was determined by the board of directors with assistance from management and, in part, on input from an independent third-party valuation firm. The board of directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company’s common stock and the general and industry-specific economic outlook. Subsequent to the Company’s IPO, the fair value of the Company’s common stock is determined based on its closing market price.